PipelineReview.com - Biotech News & Online Store - China Biopharmaceuticals Announces Robust Progress in Its Drug Development and Pipeline Program

China Biopharmaceuticals Announces Robust Progress in Its Drug Development and Pipeline Program

08 Nov 2006

Announced that it has completed various progress in both initiating and completing clinical trials in separate drug indications.

BEIJING, China | Nov 07, 2006 | China Biopharmaceuticals Holdings, Inc. (OTCBB: CHBP), a leading Chinese pharmaceutical

company focused on the development, manufacturing and distribution of innovative drugs in China, today announced that it has completed various progress in both initiating and completing clinical trials in separate drug indications.

Completion of Clinical Trials for Torasemide Tablets and Injections

CHBP announced today that all required clinical trials for both Torasemide tablets and Injections have been completed, and the Company is waiting for final manufacturing and marketing approval from the State Food and Drug Administration of China (SFDA).

The clinical trials for Torasemide for injections and tablets were conducted in five and six hospitals respectively throughout China.

Both trial results will be sent to the SFDA for marketing and manufacturing approval, which is expected to be granted by the third quarter of 2007.

Torasemide is a loop diuretics. It is commonly used in conditions such as heart failure, where the pumping mechanism of the heart is less effective. Torasemide is used to relieve the symptoms of heart failure, such as the shortness of breath seen with fluid on the lungs. At higher doses, the amount of water drawn from the blood into the urine is much greater; therefore Torasemide is also used when there is reduced production of urine in patients with kidney failure, and liver failure.

Diuretics is thought as the first choice of drug treating primary hypertension. Currently, there are 160 million people suffering with hypertension in China, and 10 million people suffering with heart failure, kidney failure, and liver failure. If granted production approval, CHBP will be the one of two pharmaceuticals companies producing Torasemide for injections in China up to 2013, and the one of four pharmaceuticals companies producing Torasemide tablets in China up to 2012, in accordance with Chinese SFDA current policies.

Highlighted Links
http://www.cbioinc.com

Initiation of Clinical Trials for Flucloxacillin Magnesium

In addition, CHBP announced that it has started the clinical trials for one of its new drugs, Flucloxacillin Magnesium. The trials will be conducted in six hospitals throughout China. All required clinical trials are to be completed within one year.

Flucloxacillin Magnesium is a semi-synthetic penicillin derived from 6-amino-penicillanic acid and is the latest of the series of penicillinase stable penicillin. It exhibits bactericidal activity against all Gram-positive organisms (with the exception of Strep.faecalis) e.g. Haemolytic streptococci, staphylococci, streptococcus pneumonia and N. gonorrhea. Its anti-staphylococcal activity is not affected by penicillinase, and as Flucloxacillin Magnesium is active against virtually all strains of Staph. aureus (methicillin-resistant strains being the only exception), it is particularly indicated in the treatment of staphylococcal infections.

In China, according to independent sources, the market size for all penicillin products in China is approximately RMB 20 billion Yuan, increasing by approximately 10% per year.

CHBP is the only company approved for clinical trials of this drug in China. If granted production approval, in accordance with Chinese SFDA current policies, CHBP will have at least a 4-year manufacturing rights exclusive for this drug in China.

"Mr. An Lufan, CHBP President and COO, stated, "This clinical progress report further demonstrates CHBP's leading R&D capabilities, robust product pipeline and CHBP's R&D team's ability to successfully navigate the drug testing and approval process. If approved by the SFDA, these 3 drug products will have the potential to help millions of patients in China."

Mr. Chris Peng Mao, CHBP Chairman, further stated, "We are very excited about starting the trials for Flucioxacillin which will, if successful and approved by the SFDA, give CHBP an exclusive drug in a very large market. It also demonstrates that our R&D division is interfacing well with one of our manufacturing facilities."

About China Biopharmaceuticals Holdings

China Biopharmaceutical Holdings, Inc. (OTCBB: CHBP) is a research driven pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases.

CHBP is a US public company with operating subsidiaries and senior management based in China.

For further information, please visit our website at www.cbioinc.com.

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

CONTACT:
Chris Peng Mao
CEO
86-10-8525-1616
Email Contact

SOURCE: China Biopharmaceuticals Holdings, Inc

Search in our News Channels

Search in our Online Store